HighTide says Phase III HTD1801 diabetes trial results published in NEJM Evidence

• HighTide Therapeutics highlighted Phase III SYMPHONY-2 results for HTD1801 with metformin in type 2 diabetes, published in NEJM Evidence.
• An NEJM Evidence editorial cited the trial’s randomized design, framing HTD1801 as a model for validating TCM-derived drugs.
• Commercialization planning accelerated for HTD1801, with talks under way for China out-licensing tied to upfront, milestones, royalties.
• No binding deal has been signed, leaving timing and scope of any China partnership uncertain.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hightide Therapeutics Inc. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260710-12241481), on July 10, 2026, and is solely responsible for the information contained therein.